| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Necitumumab Basic information |
| Product Name: | Necitumumab | | Synonyms: | IMC-11F8/LY301221;Necitumumab;Research Grade Necitumumab(DHB86901);Necitumumab (anti-EGFR);Research Grade Necitumumab | | CAS: | 906805-06-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Necitumumab Structure]() |
| | Necitumumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Necitumumab Usage And Synthesis |
| Uses | Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc[1]. | | Clinical Use | IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic
epidermal growth factor receptor (EGFR) expressing
squamous non-small cell lung cancer | | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use. | | Metabolism | The elimination routes of necitumumab are only partially
documented, and involve degradation to peptides after
being internalised into its target cells, proteolysis within
the liver or the reticuloendothelial system, as well as
nonspecific endocytosis. | | References | [1] Garnock-Jones KP. Necitumumab: First Global Approval. Drugs. 2016 Feb;76(2):283-9. DOI:10.1007/s40265-015-0537-0 |
| | Necitumumab Preparation Products And Raw materials |
|